ArticleNeurosurgical review2026
Flow reversal strategy for symptomatic vertebrobasilar dolichoectasia: a single-center experience with ECA-RA-PCA bypass.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symptomatic vertebrobasilar dolichoectasia (VBD) is associated with an extremely poor natural prognosis and presents significant clinical challenges. This study aims to evaluate the safety and efficacy of a flow reversal strategy based on extracranial carotid artery-radial artery-posterior cerebral artery (ECA-RA-PCA) bypass, combined with individualized proximal parent artery intervention, for the treatment of symptomatic VBD. We retrospectively analyzed the clinical data of 23 consecutive patients with symptomatic VBD treated with microsurgery between October 2019 and July 2025. Patients were categorized into ischemia-dominant (n = 13), compression-dominant (n = 8), and hemorrhage-dominant (n = 2) subtypes based on their primary clinical presentation. All patients underwent ECA-RA-PCA bypass. Differentiated treatment strategies were implemented based on clinical subtypes: ischemia-dominant patients mostly received bypass alone (12/13, 92.3%), whereas compression-dominant (6/8, 75.0%) and hemorrhage-dominant (2/2, 100%) patients primarily underwent bypass combined with proximal occlusion. Surgical success was achieved in all cases, with a graft patency rate of 100% intraoperatively and during follow-up. Over a median follow-up of 38 months (IQR 23-51), 69.6% (16/23) of patients achieved radiographic improvement (43.5% with lesion regression and 26.1% with obliteration), with no instances of aneurysm rupture or progression. The median Modified Rankin Scale (mRS) score improved from 3 (IQR 2-4) preoperatively to 2 (IQR 1-4) at the last follow-up. The overall favorable clinical outcome rate was 69.6%; the ischemia-dominant group achieved the highest favorable rate (84.6%), followed by the compression-dominant group (62.5%). Major complications included brainstem infarction (30.4%) and pneumonia (39.1%), both of which occurred at higher rates in the compression and hemorrhage groups. For complex symptomatic VBD unsuitable for conventional endovascular treatment, an individualized flow reversal strategy based on ECA-RA-PCA bypass and clinical subtyping is a feasible and effective therapeutic option, albeit with inherent high surgical risks. This strategy maintains long-term flow patency, promotes benign remodeling of the diseased vessel, and may be associated with favorable long-term neurological outcomes in carefully selected patients.
Indexed as
Identifiers
42286207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.